The board of directors of SSY Group Limited announced that the Group's Norepinephrine bitartrate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Norepinephrine bitartrate is an adrenergic receptors agonist, which is mainly used clinically in anti-shock by causing extreme contraction of blood vessels to increase blood pressure and coronary blood flow as well as by strengthening myocardial contraction and increasing cardiac output.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.8 HKD | +0.63% | +2.13% | -2.83% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.83% | 1.81B | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+16.11% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market